EF Hutton analyst Michael Albanese initiates coverage on Onfolio Holdings (NASDAQ:ONFO) with a Buy rating and announces Price Target of $3.
Reported Sunday, BridgeBio Pharma Presented Results From The Exploratory Cardiac Magnetic Resonance Imaging Substudy Of ATTRibute-CM, Its Phase 3 trial Of Acoramidis In ATTR-CM
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression
- The data
